Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Cortex Pharmaceuticals has received two patents, which protect the next generation of AMPAKINE compounds, from the USPTO.
Subscribe to our email newsletter
The new AMPAKINE patents cover a series of compounds including CX2007 and CX2076, which exhibit a long duration of action and pharmacokinetic properties through August 2028.
The company received a composition-of-matter patent and a divisional patent covering methods of use, including the treatment for a range of breathing disorders.
Cortex president and CEO Mark Varney said one patent defines a new composition-of-matter patent, while the other protects the ability to use the compounds for the treatment of opioid-induced respiratory depression and other related breathing disorders.
"The CX2007 and CX2076 patent provides added protection to our portfolio of patents covering specific AMPAKINE molecules and their uses, particularly in breathing-related disorders such as opioid-induced respiratory depression," Varney added.